FindTrial
Sign In

Observation study to asses the effect of SGLT2 inhibitors on cardiac uptake of FDG

The effect of SGLT2 inhibitors on cardiac uptake of [18F]FDG in diabetes patients with lymphoma or multiple myeloma: A prospective observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004869
Enrollment
30
Registered
2020-04-01
Start date
2020-03-27
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ulsan Univeristy Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient is being treated with SGLT2 inhibitor for type 2 diabetes 2. Patient has been diagnosed with lymphoma or multiple myeloma by a hemato-oncologist 3. Patient is scheduled to undergo [18F]FDG PET/CT exam

Exclusion criteria

Exclusion criteria: 1. Patient has atrial fibrillation or history of cardiovascular event within the last 6 months 2. Patient is using insulin or has a history of using insulin 3. Uncontrolled hypertension (>160/110) 4. Pregnancy

Design outcomes

Primary

MeasureTime frame
Visual scoring of cardiac uptake of fluorodeoxyglucose—

Secondary

MeasureTime frame
Standardized uptake value of myocardium—

Countries

Korea, Republic of

Contacts

Public ContactJae-Cheol Jo

Ulsan Univeristy Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026